Sloning Biotechnology and Microsynth Announce Exclusive Distribution Partnership for Switzerland
News Jun 04, 2007
Microsynth will exclusively market and sell Sloning's gene synthesis service (Slonomics™) and the product family of mutant libraries (Slonomax™) in Switzerland.
“We are very pleased that Microsynth will join our global network of qualified distributors. With its strong technological expertise, market position and service philosophy Microsynth is the ideal partner for Sloning to develop the Swiss market,” stated Thomas Matthes, the company CBO.
Dr. Tobias Schmidheini, founder and CEO of Microsynth said, “Sloning´s products and services perfectly complement our portfolio. It’s a strategic development for our organization. We are looking forward to offering Sloning´s products to our customer base.”
Scientists have found that bowel cancer is actually five distinct diseases, with different biological characteristics which affect how they respond to drugs. The new genetic test can diagnose a person’s specific type of bowel cancer in a matter of hours and help tailor treatments to each individual disease.READ MORE
Genome-wide association studies (GWAS) look at large populations to find genes that contribute to common, multi-gene traits like height or obesity. These comprehensive studies frequently turn up large numbers of tiny genetic variations that occur more often in people who are tall, obese, etc. So which genes should scientists investigate further?READ MORE